Compare Abeona Therapeutics Inc (ABEO) vs Palantir Technologies Inc (PLTR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Palantir Technologies Inc — how do they compare? Abeona Therapeutics Inc trades at $6.76 (market cap $373.32M), while Palantir Technologies Inc trades at $130.39 (market cap $322.13B). The key difference: Palantir Technologies Inc is far larger — about 862.9× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Palantir Technologies Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | PLTR | |
|---|---|---|
Market Cap | $373.32M | $322.13B |
Sector | Health | Technology |
52-Week High | $7.23 | $207.18 |
52-Week Low | $4.17 | $107.27 |
Enterprise Value | $228.22M | $314.31B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
PLTR trades at $134.37, up 4.03% today, with a bullish technical signal and strong earnings momentum after beating estimates for three consecutive quarters. Revenue grew to $4.48B in 2025, with net income reaching $1.63B, though valuation ratios remain elevated. Recent news highlights AI partnerships with Nvidia and expansion in Mexico, driving positive sentiment.
Outlook is positive given robust earnings growth and AI adoption, but high P/E of 148.92 poses valuation risk. Analyst consensus price target is $185.67, with 46% buy ratings. Key risks include competitive pressures and reliance on government contracts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Palantir Technologies Inc
Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →
